Patents Represented by Attorney Viviana Pretty, Schroeder & Poplawski, PC Amzel
  • Patent number: 5972337
    Abstract: A polypeptide has the antibody binding activity of the 46 Kdalton HMFG antigen and/or homology to at least one of the light chains of clotting factors V and VIII and/or contains RGD and/or EGF-like segments. The polypeptide is provided as a recombinant and/or glycosylated and/or fusion protein. An antibody has high affinity for specificity epitopes of the polypeptide of the invention. Polynucleotide segments encode the polypeptide, recombinant and fusion protein of the invention or fragments thereof, and immunoassay kits comprise the antibodies and/or polypeptides of the invention and other components. In vivo, ex vivo, and in vitro methods of therapy, vaccination and diagnosis utilize the polypeptide, fusion protein anti-sense nucleotides, antibodies or and polynucleotides of the invention.
    Type: Grant
    Filed: December 3, 1993
    Date of Patent: October 26, 1999
    Assignee: Cancer Research Fund of Contra Costa
    Inventors: Robeto L. Ceriani, Jerry A. Peterson, David J. Larocca
  • Patent number: 5952184
    Abstract: The invention provides a method for determining platelet function in a mammal comprising providing platelets from the mammal, contacting the platelets in suspension with at least one immobilised ECM protein or an effective fragment or analog thereof while applying to the platelets an effective mechanical stimulus for an effective period of time and determining the platelet activation produced.The invention provides a method for monitoring the efficacy of pharmacological agents affecting platelet function in vivo and in vitro.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: September 14, 1999
    Assignee: Alberta Cancer Board
    Inventors: Andrew R. E. Shaw, Michael W. Stewart